Robert Ho
Keine laufenden Positionen mehr
Karriereverlauf von Robert Ho
Ehemalige bekannte Positionen von Robert Ho
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| THIRD HARMONIC BIO, INC. | Finanzdirektor/CFO | 01.03.2022 | 10.11.2023 |
| Investor Relations Kontakt | 01.03.2022 | 10.11.2023 | |
| Treasurer | - | 10.11.2023 | |
| NEUROGENE INC. | Comptroller/Controller/Auditor | 16.03.2020 | 01.03.2022 |
| Finanzdirektor/CFO | 16.03.2020 | 01.03.2022 | |
| Unternehmenssekretär | - | 01.03.2022 | |
| DAVITA INC. | Finanzdirektor/CFO | - | - |
Morgan Stanley & Co. LLC
 Morgan Stanley & Co. LLC Investment Banks/BrokersFinance Morgan Stanley & Co. LLC is a registered broker-dealer subsidiary of Morgan Stanley Domestic Holdings, Inc., ultimately owned by Morgan Stanley (NYSE: MS) in the US. Headquartered in New York City, the firm was founded in 1987 and provides debt and equity services including underwriting, M&A advice, securities dealing and brokerage and trade execution. Their client base ranges from large global institutional investors to hedge funds at the cutting edge of innovation in the industry. | Corporate Officer/Principal | - | - |
Ausbildung von Robert Ho
| University of Notre Dame | Undergraduate Degree |
| University of Virginia Darden School of Business | Masters Business Admin |
Statistik
International
| Vereinigte Staaten | 7 |
Operativ
| Director of Finance/CFO | 3 |
| Comptroller/Controller/Auditor | 1 |
| Corporate Secretary | 1 |
Sektoral
| Health Technology | 3 |
| Consumer Services | 3 |
| Finance | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| DAVITA INC. | Health Services |
| THIRD HARMONIC BIO, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Neoleukin Therapeutics, Inc.
 Neoleukin Therapeutics, Inc. BiotechnologyHealth Technology Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA. | Health Technology |
Morgan Stanley & Co. LLC
Morgan Stanley & Co. LLC Investment Banks/BrokersFinance Morgan Stanley & Co. LLC is a registered broker-dealer subsidiary of Morgan Stanley Domestic Holdings, Inc., ultimately owned by Morgan Stanley (NYSE: MS) in the US. Headquartered in New York City, the firm was founded in 1987 and provides debt and equity services including underwriting, M&A advice, securities dealing and brokerage and trade execution. Their client base ranges from large global institutional investors to hedge funds at the cutting edge of innovation in the industry. | Finance |
